Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
ABO-incompatible kidney transplantation (ABOic KT) is increasingly feasible with modern desensitization, but patients with very high baseline isoagglutinin titers remain challenging.
We retrospectively reviewed 15 patients from two centers who underwent ABOic KT with baseline titers ≥1:1024. All received rituximab, plasmapheresis, and protocol-based immunosuppression. Outcomes assessed included bleeding, biopsy-proven allograft rejection (BPAR), infections, graft function, and survival.
Median age was 53 years (13 males, 2 females). All but one achieved preoperative titers ≤1:32 after a median of 10 apheresis sessions (range: 7–16). Two patients developed severe postoperative bleeding requiring graft nephrectomy. Seven patients experienced BPAR (T cell– or antibody-mediated); notably, only one had a titer of 1:1024 at rejection, while the others had ≤1:16. In regard to opportunistic viral infection, 7 patients developed both CMV and BK viremia, 2 had CMV alone, and 2 had BK alone. During long-term follow-up, three patients lost graft function—two due to chronic rejection at 6 and 15 years and one due to sepsis-related acute kidney injury at 15 years. Two patients died, one from cardiovascular disease at 1.2 years and another from pneumonia at 6 years post-transplant.
Despite extremely high baseline isoagglutinin titers, ABOic KT can achieve acceptable long-term outcomes. However, careful pretransplant desensitization and vigilant posttransplant monitoring for bleeding and infectious complications are essential.
